

May 18, 2024

Listing Department **BSE LIMITED**P J Towers, Dalal Street,

Mumbai–400 001

Listing Department Code: ZYDUSLIFE

Code: 532321

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, C/1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai–400 051

Re.: Newspaper publication

Dear Sir / Madam,

Please find attached the newspaper cutting with regard to publication of extracts of audited financial results for the quarter / year ended on March 31, 2024 in Financial Express on May 18, 2024.

Please find the same in order.

Thanking you,

Yours faithfully,
For, ZYDUS LIFESCIENCES LIMITED

DHAVAL N. SONI COMPANY SECRETARY

Encl.: As above





Zydus Lifesciences Limited

Registered Office: Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Near Vaishnodevi Circle, Sarkhej- Gandhinagar Highway, Ahmedabad - 382481 Tel. No.: (+91-79) 4804 0000 Website: www.zyduslife.com

CIN: L24230GJ1995PLC025878

Sr. No.	Particulars	THE PARTY OF THE P	Rupees in Million					
		3 Months ended 31/03/2024	Preceding 3 Months ended 31/12/2023	Corresponding 3 Months ended 31/03/2023 in the previous year	Year ended 31/03/2024	Previous year ended 31/03/2023		
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Audited)		
1	Total income from operations	55,338	45,052	50,106	195,474	172,374		
2	Net Profit for the period before exceptional items and tax	15,470	9,255	10,871	48,231	31,939		
3	Net Profit for the period after exceptional items but before tax	15,470	9,255	4,858	48,089	25,897		
4	Net Profit for the period from continuing operations	11,791	100000000000000000000000000000000000000	2,988	38,365	19,649		
5	Profit/ [Loss] after tax from discontinued operations	32	31080	(22)	230	(46)		
4	New Profit for the period after tax and Non-Controlling Interest	11,823	7,896	2,966	38,595	19,603		
7	Total Comprehensive Income for the period after tax and Non-Controlling Interest	10,118	8,099	3,015	36,594	16,459		
8	Pairt-up equity share capital (Face value Re. 1/-)	1,006	1,012	1,012	1,006	1,012		
	Reserves excluding Revaluation Reserve (i.e. Other Equity) Earnings per share for continuing operations (not annualised for the quarter)				197,289	174,146		
100000000000000000000000000000000000000	Basic (Rs.)	11.66	7.59	2.95	37.91	19.35		
	Diluted (Rs.) Earnings per share for continuing & discontinued operations (not annualised for the quarter)	11.66	7.59	2.95	37.91	19.35		
L MODE STOCKED		11.69	7.80	2.93	38.14	19.30		
THE PERSON NAMED IN COLUMN 1	Basic (Rs.) Diluted (Rs.)	11.69	7.80	2.93	38.14	1000000		

Note:

[1] The above is an extract of the detailed format of Quarterly/ Yearly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015. The full format of the Quarterly/ Yearly Financial Results are available on the Company's website: www.zyduslife.com, on the website of BSE [www.bseindia.com] and on the website of NSE [www.nseindia.com].

By Order of the Board, For Zydus Lifesciences Limited,

> Dr. Sharvil P. Patel Managing Director DIN: 00131995

Date: May 17, 2024 Place: Muscat, Oman



Zydus Lifesciences Limited

Registered Office: Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Near Vaishnodevi Circle, Sarkhej-Gandhinagar Highway, Ahmedabad - 382481

Tel. No.: (+91-79) 4804 0000 Website: www.zyduslife.com

CIN: L24230GJ1995PLC025878

Extract of Consolidated Financial Results for the Quarter and Von- Ended &

Sr. No.	Particulars Particulars	STATE OF THE PARTY	Rupees in Million					
		3 Months ended 31/03/2024	Preceding 3 Months ended 31/12/2023	Corresponding 3 Months ended 31/03/2023 in the previous year	Year ended 31/03/2024	Previous year ended 31/03/2023		
1	Total income from operations	(Unaudited)		(Unaudited)	(Audited)	(Audited)		
2	Net Profit for the period before exceptional items and tax	55,338	VIII SALIDO DE ONDO DE	50,106	195,474	172,374		
3	Net Profit for the period after exceptional items and tax	15,470	9,255	10,871	48,231	31,939		
4	Net Profit for the period after exceptional items but before tax Net Profit for the period from continuing operations	15,470	9,255	4,858	48,089	25,897		
5	Profit/ (Loss) after tay from discounts	11,791	7,678	2,988	38,365	19,649		
6	Profit/ [Loss] after tax from discontinued operations	32	218	(22)	230	(46)		
7	Net Profit for the period after tax and Non-Controlling Interest	11,823	7,896	2,966	38,595	19,603		
-	Total Comprehensive Income for the period after tax and Non-Controlling Interest	10,118	8,099	3,015	36,594	16,459		
0	Paid-up equity share capital (Face value Re. 1/-)	1,006	1,012	1,012	1,006	1,012		
10	Reserves excluding Revaluation Reserve (i.e. Other Equity) Earnings per share for continuing operations (not annualised for the quarter)				197,289	The state of the s		
a	Basic (Rs.)	11.66	7.59	2.95	37.91	19.35		
	Diluted (Rs.) Earnings per share for continuing & discontinued operations (not annualised for the quarter)	11.66		The second second	37.91			
a	Basic (Rs.) Diluted (Rs.)	11.69	7.80	2.93	38.14	19.30		
Note:	Diluted (r.S.)	11.69	7.80		38.14			

Note:

[1] The above is an extract of the detailed format of Quarterly/ Yearly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015. The full format of the Quarterly/ Yearly Financial Results are available on the Company's website: www.zyduslife.com, on the website of BSE [www.bseindia.com] and on the website of NSE [www.nseindia.com].

> By Order of the Board, For Zydus Lifesciences Limited,

> > Dr. Sharvil P. Patel **Managing Director** DIN: 00131995

Date: May 17, 2024 Place: Muscat, Oman